Manufacturers report positive results for pegcetacoplan for paroxysmal nocturnal haemoglobinuria in phase 3 PRINCE study

In the study, pegcetacoplan, a cyclic peptide that inhibits complement activation at the level of complement factor C3, was superior to standard of care for haemoglobin stabilisation (86% vs 0%, p<0.0001).

Source:

Biospace Inc.